Global Genetic disorders Partnering 2012-2018: Deal trends, players and financials

Publisher Name :
Date: 01-Oct-2018
No. of pages: 500
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Genetic disorders Partnering 2012-2018: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the genetic disorders partnering deals and agreements entered into by the worlds leading healthcare companies

Global Genetic Disorders Partnering 2012 to 2018 provides the full collection of Genetic Disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Trends in Genetic Disorders partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Genetic Disorders partnering agreement structure

Genetic Disorders partnering contract documents

Top Genetic Disorders deals by value

Most active Genetic Disorders dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genetic Disorders dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genetic Disorders dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genetic Disorders deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genetic Disorders deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2012. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.

Report scope

Global Genetic Disorders Partnering 2012 to 2018 is intended to provide the reader with an in-depth understanding and access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide.

Global Genetic Disorders Partnering 2012 to 2018 includes:

Trends in Genetic Disorders dealmaking in the biopharma industry since 2012

Analysis of Genetic Disorders deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Genetic Disorders deal contract documents

Comprehensive access to over 3500 Genetic Disorders deal records

The leading Genetic Disorders deals by value since 2012

Most active Genetic Disorders dealmakers since 2012

The report includes deals for the following indications: Cystic Fibrosis (CF), Down syndrome, Fragile X Syndrome, Hereditary angioedema, Huntington's disease, Rare genetic disorders, Neurofibromatosis, Sickle cell disease, plus other genetic indications.

In Global Genetic Disorders Partnering 2012 to 2018, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Genetic Disorders Partnering 2012-2018 report provides comprehensive access to available deals and contract documents for over 400 genetic disorders deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Genetic Disorders Partnering 2012 to 2018 provides the reader with the following key benefits:

In-depth understanding of Genetic Disorders deal trends since 2012

Access Genetic Disorders deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Genetic Disorders partner companies

Comprehensive access to over 750 links to actual Genetic Disorders deals entered into by the world's biopharma companies

Indepth review of Genetic Disorders deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Genetic Disorders opportunities

Uncover companies actively partnering Genetic Disorders opportunities

Global Genetic disorders Partnering 2012-2018: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genetic Disorders dealmaking
2.1. Introduction
2.2. Genetic Disorders partnering over the years
2.3. Genetic Disorders partnering by deal type
2.4. Genetic Disorders partnering by industry sector
2.5. Genetic Disorders partnering by stage of development
2.6. Genetic Disorders partnering by technology type
2.7. Genetic Disorders partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genetic Disorders partnering
3.1. Introduction
3.2. Disclosed financials terms for Genetic Disorders partnering
3.3. Genetic Disorders partnering headline values
3.4. Genetic Disorders deal upfront payments
3.5. Genetic Disorders deal milestone payments
3.6. Genetic Disorders royalty rates

Chapter 4 - Leading Genetic Disorders deals and dealmakers
4.1. Introduction
4.2. Most active in Genetic Disorders partnering
4.3. List of most active dealmakers in Genetic Disorders
4.4. Top Genetic Disorders deals by value

Chapter 5 - Genetic Disorders contract document directory
5.1. Introduction
5.2. Genetic Disorders partnering deals where contract document available

Chapter 6 - Genetic Disorders dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Genetic Disorders therapeutic target

Appendices
Appendix 1 - Directory of Genetic Disorders deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Genetic Disorders deals by deal type 2012 to 2018
Appendix 3 - Directory of Genetic Disorders deals by stage of development 2012 to 2018
Appendix 4 - Directory of Genetic Disorders deals by technology type 2012 to 2018
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Tables and Figures

Figure 1: Genetic Disorders partnering since 2012
Figure 2: Genetic Disorders partnering by deal type since 2012
Figure 3: Genetic Disorders partnering by industry sector since 2012
Figure 4: Genetic Disorders partnering by stage of development since 2012
Figure 5: Genetic Disorders partnering by technology type since 2012
Figure 6: Genetic Disorders partnering by indication since 2012
Figure 7: Genetic Disorders deals with a headline value
Figure 8: Genetic Disorders deals with upfront payment values
Figure 9: Genetic Disorders deals with milestone payment
Figure 10: Genetic Disorders deals with royalty rates
Figure 11: Active Genetic Disorders dealmaking activity- 2012 to 2018
Figure 12: Top Genetic Disorders deals by value since 2012
  • Musculoskeletal Disorders Therapeutics Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 20-Feb-2019        Price: US 3000 Onwards        Pages: 147
    Musculoskeletal Disorders Therapeutics Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Musculoskeletal Disorders Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Musculoskeletal Disorders Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides a......
  • Global Anti-inflammatory Therapeutics Market Research Report 2019
    Published: 20-Feb-2019        Price: US 2900 Onwards        Pages: 90
    Anti-inflammatory therapeutics are primarily used to reduce inflammation. These drugs are types of analgesics that are used for reducing pain. The global anti-inflammatory therapeutics market will grow steadily at a CAGR of over 6% by 2021. This market research analysis identifies the increase in the prevalence of immune-mediated inflammatory disease (IMID) as one of the primary growth factors for this market. IMID includes a group of disabling conditions that share a common inflammatory ......
  • Global Microbiome Therapeutics Market Growth 2019-2024
    Published: 20-Feb-2019        Price: US 3660 Onwards        Pages: 175
    The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bact......
  • Global Acute Ischemic Stroke Therapeutics Market Research Report 2019
    Published: 20-Feb-2019        Price: US 2900 Onwards        Pages: 98
    AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternat......
  • Global Venous Leg Ulcers Treatment Market Insights, Forecast to 2025
    Published: 19-Feb-2019        Price: US 3900 Onwards        Pages: 118
    The global Venous Leg Ulcers Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Venous Leg Ulcers Treatment market based on company, product type, end user and key regions. This report studies the global market size of Venous Leg Ulcers Treatment in key regions like North America, Europe, Asia Pacific, Central & South......
  • Global Substance Abuse Treatment Market Insights, Forecast to 2025
    Published: 19-Feb-2019        Price: US 3900 Onwards        Pages: 119
    The global Substance Abuse Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Substance Abuse Treatment market based on company, product type, end user and key regions. This report studies the global market size of Substance Abuse Treatment in key regions like North America, Europe, Asia Pacific, Central & South Ameri......
  • Ozone Treatment Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 18-Feb-2019        Price: US 3000 Onwards        Pages: 137
    Ozone Treatment Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Ozone Treatment industry with a focus on the Chinese market. The report provides key statistics on the market status of the Ozone Treatment manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Ozone Treatment ma......
  • Global Peptide Therapeutics Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Feb-2019        Price: US 3480 Onwards        Pages: 135
    Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are distinguished from proteins on the basis of size, and as a benchmark can be understood to contain approximately 50 amino acids or less. In this report, we study the peptide-based drugs. Scope of the Report: In the last several years, global market of ......
  • Global Hormone Replacement Therapy Market Status and Future Forecast 2015-2024
    Published: 15-Feb-2019        Price: US 4500 Onwards        Pages: 146
    Summary Key Content of Chapters (Including and can be customized) Part 1: Market Overview, Development, and Segment by Type, Application & Region Part 2: Global Market by company, Type, Application & Geography Part 3-4: Asia-Pacific Market by company, Type, Application & Geography Part 5-6: Europe Market by company, Type, Application & Geography Part 7-8: North America Market by company, Type, Application & Geography Part 9-10: South Ameri......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs